ASTHMA CLINICAL RESEARCH NETWORK

这项申请建议继续调查人员的参与 在纽约市中心由六个中心组成的互动网络中， 哮喘临床研究网络(ACRN)进行的研究 治疗哮喘的新疗法以及将研究结果传播给 实践社区。有人建议需要这样一个网络 哮喘的死亡率、发病率、患病率和成本都在增加， 研究表明哮喘与呼吸道有关 炎症，以及潜在的发展速度的加快 有效，但也可能代价高昂的治疗方法。定义地点 在这些新的治疗方法中，被认为需要多中心合作 研究对象反映了美国的多样性。 人口。在最初的5年里，ACRN建立了一个互动的 基础设施，并在纽约哈莱姆医院增加了一个研究网站， 服务于以少数族裔为主的人群。ACRN完成 并发表了定期使用β-激动剂的疗效试验。 轻度哮喘(袋)和秋水仙碱的替代疗效 对中度哮喘患者使用吸入性皮质类固醇(ICS)。现在是时候了 正在进行试验，比较长效β-激动剂ICS和 在中到重度哮喘中，两者联合使用。我们马上就要 开始第5项研究，以确定不同剂量的ICS的等量 对皮质醇分泌的影响。这些研究已在以下网址发表 ATS、ACCP和AAAAI的会议，AS有10-12项辅助研究 分析临床研究的绩效。ACRN还 报告了对巴克斯研究的分组分析的发现： 具有不同β-肾上腺素能受体基因类型的受试者 受沙丁胺醇常规使用的影响不同。 这项申请建议纽约市哮喘协会继续参与 多中心合作试验中的临床研究小组 ACRN。建议的研究包括临床试验的比较。 不同剂量吸入糖皮质激素的疗效比较 全身效应，一项关于经常使用吸入性β-药物的前瞻性研究- 按β-肾上腺素能基因分层的受试者中的激动剂 受体，一种白三烯途径拮抗剂的疗效研究 在减少或消除吸入性皮质类固醇治疗方面 在轻度或中度持续性哮喘的受试者中，以及其他研究 在此应用程序中进行了简要说明，但由 ACRN指导委员会对新信息或新闻稿的回应 新的治疗形式。

This application proposes to continue the participation of investigators at the New York City Center in an interactive network of six centers, the Asthma Clinical Research Network (ACRN) in conducting studies of novel therapies for asthma and in disseminating findings to the practicing community. The need for such a network was suggested by increases in the mortality, morbidity, prevalence, and costs of asthma, by research studies showing that asthma is linked to airway inflammation, and by the accelerating rate of development of potentially effective, but also potentially costly treatments. Defining the place of these new therapies was seen as requiring collaborative, multi-center studies examining subjects reflecting the diversity of the U.S. population. In its first 5 years, the ACRN established an interactive infrastructure and added a research site at Harlem Hospital, New York, which serves a predominantly minority population. The ACRN completed and published trials of the effects of regular use of a beta-agonist in mild asthma ( BAGS ) and of the efficacy of colchicine as an alternate to an inhaled corticosteroid (ICS) in moderate asthma. It is now conducting trials comparing a long-acting beta-agonist, an ICS, and the combination of the two in moderate to severe asthma. We are about to start a 5th study to establish doses of different ICS with equivalent effects on cortisol secretion. These studies have been presented at meetings of the ATS, ACCP, and AAAAI, as have 10-12 ancillary studies analyzing the performance of clinical research. The ACRN has also reported its findings from subgroup analysis of the BAGS study: that subjects with different genotypes for the beta-adrenergic receptor are differently affected by regular use of albuterol. This application proposes continued participation of the NYC Asthma Clinical Research group in the multicentered, collaborative trials of the ACRN. The studies proposed include a comparison of the clinical efficacy of doses of different inhaled corticosteriods with equal systemic effects, a prospective study of regular use of an inhaled beta- agonist in subjects stratified by genotype for the beta-adrenergic receptor, a study of the efficacy of a leukotriene pathway antagonist in enabling reduction or elimination of inhaled corticosteriod therapy in subjects with mild or moderate persistent asthma, and other studies illustrated briefly in this application, but modified or replaced by the ACRN Steering Committee in response to new information or the release of new forms of therapy.